vs
ExlService Holdings, Inc.（EXLS）とPHIBRO ANIMAL HEALTH CORP（PAHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
ExlService Holdings, Inc.の直近四半期売上が大きい（$542.6M vs $373.9M、PHIBRO ANIMAL HEALTH CORPの約1.5倍）。ExlService Holdings, Inc.の純利益率が高く（11.1% vs 7.3%、差は3.8%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs 12.7%）。ExlService Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$106.5M vs $8.3M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 11.5%）
ExlService Holdings Inc.は保険、ヘルスケア、銀行・金融サービス、メディア、小売などの業界を対象に分析・デジタルソリューションを提供するグローバル企業で、本社はニューヨークに所在し、米国、欧州、アジア、中南米、オーストラリア、南アフリカなど世界各地に5万4000人以上の専門スタッフを擁しています。
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
EXLS vs PAHC — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $542.6M | $373.9M |
| 純利益 | $60.2M | $27.5M |
| 粗利率 | 38.6% | 35.5% |
| 営業利益率 | 14.4% | 13.5% |
| 純利益率 | 11.1% | 7.3% |
| 売上前年比 | 12.7% | 20.9% |
| 純利益前年比 | 18.9% | 762.1% |
| EPS（希薄化後） | $0.38 | $0.67 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $542.6M | $373.9M | ||
| Q3 25 | $529.6M | $363.9M | ||
| Q2 25 | $514.5M | $378.7M | ||
| Q1 25 | $501.0M | $347.8M | ||
| Q4 24 | $481.4M | $309.3M | ||
| Q3 24 | $472.1M | $260.4M | ||
| Q2 24 | $448.4M | $273.2M | ||
| Q1 24 | $436.5M | $263.2M |
| Q4 25 | $60.2M | $27.5M | ||
| Q3 25 | $58.2M | $26.5M | ||
| Q2 25 | $66.1M | $17.2M | ||
| Q1 25 | $66.6M | $20.9M | ||
| Q4 24 | $50.7M | $3.2M | ||
| Q3 24 | $53.0M | $7.0M | ||
| Q2 24 | $45.8M | $752.0K | ||
| Q1 24 | $48.8M | $8.4M |
| Q4 25 | 38.6% | 35.5% | ||
| Q3 25 | 38.5% | 32.9% | ||
| Q2 25 | 37.7% | 29.0% | ||
| Q1 25 | 38.6% | 30.1% | ||
| Q4 24 | 38.1% | 32.9% | ||
| Q3 24 | 37.8% | 32.1% | ||
| Q2 24 | 37.1% | 31.9% | ||
| Q1 24 | 37.4% | 30.2% |
| Q4 25 | 14.4% | 13.5% | ||
| Q3 25 | 14.4% | 14.1% | ||
| Q2 25 | 15.8% | 8.9% | ||
| Q1 25 | 15.7% | 9.6% | ||
| Q4 24 | 14.8% | 8.3% | ||
| Q3 24 | 14.7% | 6.8% | ||
| Q2 24 | 13.7% | 6.7% | ||
| Q1 24 | 14.1% | 7.6% |
| Q4 25 | 11.1% | 7.3% | ||
| Q3 25 | 11.0% | 7.3% | ||
| Q2 25 | 12.8% | 4.5% | ||
| Q1 25 | 13.3% | 6.0% | ||
| Q4 24 | 10.5% | 1.0% | ||
| Q3 24 | 11.2% | 2.7% | ||
| Q2 24 | 10.2% | 0.3% | ||
| Q1 24 | 11.2% | 3.2% |
| Q4 25 | $0.38 | $0.67 | ||
| Q3 25 | $0.36 | $0.65 | ||
| Q2 25 | $0.40 | $0.43 | ||
| Q1 25 | $0.40 | $0.51 | ||
| Q4 24 | $0.31 | $0.08 | ||
| Q3 24 | $0.33 | $0.17 | ||
| Q2 24 | $0.28 | $0.02 | ||
| Q1 24 | $0.29 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $328.4M | $74.5M |
| 総負債低いほど良い | $298.6M | $624.2M |
| 株主資本純資産 | $912.7M | $332.4M |
| 総資産 | $1.7B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.33× | 1.88× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $328.4M | $74.5M | ||
| Q3 25 | $390.1M | $85.3M | ||
| Q2 25 | $353.3M | $77.0M | ||
| Q1 25 | $331.4M | $70.4M | ||
| Q4 24 | $340.6M | $67.1M | ||
| Q3 24 | $325.8M | $89.8M | ||
| Q2 24 | $276.1M | $114.6M | ||
| Q1 24 | $246.2M | $98.7M |
| Q4 25 | $298.6M | $624.2M | ||
| Q3 25 | $354.8M | $628.0M | ||
| Q2 25 | $260.0M | $631.7M | ||
| Q1 25 | $307.3M | $635.4M | ||
| Q4 24 | $288.5M | $639.1M | ||
| Q3 24 | $344.7M | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
| Q4 25 | $912.7M | $332.4M | ||
| Q3 25 | $952.4M | $311.7M | ||
| Q2 25 | $1.1B | $285.7M | ||
| Q1 25 | $1.0B | $266.0M | ||
| Q4 24 | $929.9M | $246.8M | ||
| Q3 24 | $907.6M | $258.5M | ||
| Q2 24 | $852.6M | $256.6M | ||
| Q1 24 | $803.3M | $270.1M |
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.6B | $966.3M | ||
| Q2 24 | $1.5B | $982.2M | ||
| Q1 24 | $1.4B | $979.0M |
| Q4 25 | 0.33× | 1.88× | ||
| Q3 25 | 0.37× | 2.01× | ||
| Q2 25 | 0.25× | 2.21× | ||
| Q1 25 | 0.30× | 2.39× | ||
| Q4 24 | 0.31× | 2.59× | ||
| Q3 24 | 0.38× | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $117.4M | $19.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $106.5M | $8.3M |
| FCFマージンFCF / 売上 | 19.6% | 2.2% |
| 設備投資強度設備投資 / 売上 | 2.0% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | 1.95× | 0.70× |
| 直近12ヶ月FCF直近4四半期 | $298.1M | $47.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $117.4M | $19.4M | ||
| Q3 25 | $120.7M | $9.3M | ||
| Q2 25 | $109.4M | $21.3M | ||
| Q1 25 | $3.2M | $43.2M | ||
| Q4 24 | $105.3M | $3.1M | ||
| Q3 24 | $110.1M | $12.6M | ||
| Q2 24 | $74.9M | $28.4M | ||
| Q1 24 | $-21.9M | $11.4M |
| Q4 25 | $106.5M | $8.3M | ||
| Q3 25 | $106.4M | $-4.5M | ||
| Q2 25 | $95.0M | $8.1M | ||
| Q1 25 | $-9.7M | $35.4M | ||
| Q4 24 | $95.3M | $-4.7M | ||
| Q3 24 | $97.3M | $3.0M | ||
| Q2 24 | $62.8M | $15.4M | ||
| Q1 24 | $-33.1M | $1.7M |
| Q4 25 | 19.6% | 2.2% | ||
| Q3 25 | 20.1% | -1.2% | ||
| Q2 25 | 18.5% | 2.1% | ||
| Q1 25 | -1.9% | 10.2% | ||
| Q4 24 | 19.8% | -1.5% | ||
| Q3 24 | 20.6% | 1.2% | ||
| Q2 24 | 14.0% | 5.6% | ||
| Q1 24 | -7.6% | 0.6% |
| Q4 25 | 2.0% | 3.0% | ||
| Q3 25 | 2.7% | 3.8% | ||
| Q2 25 | 2.8% | 3.5% | ||
| Q1 25 | 2.6% | 2.2% | ||
| Q4 24 | 2.1% | 2.5% | ||
| Q3 24 | 2.7% | 3.7% | ||
| Q2 24 | 2.7% | 4.8% | ||
| Q1 24 | 2.6% | 3.7% |
| Q4 25 | 1.95× | 0.70× | ||
| Q3 25 | 2.08× | 0.35× | ||
| Q2 25 | 1.66× | 1.24× | ||
| Q1 25 | 0.05× | 2.07× | ||
| Q4 24 | 2.08× | 0.97× | ||
| Q3 24 | 2.08× | 1.81× | ||
| Q2 24 | 1.63× | 37.80× | ||
| Q1 24 | -0.45× | 1.36× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
